P-159 Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-Gastric04): A randomized phase 3 study
K. Shitara, F. Barlaskar, F. Franke, Yoshiaki Kawaguchi, L. Shen, Takahiro Kamio, Gerold Meinhardt, Josep Tabernero
Topics & Concepts
MedicineTrastuzumabInternal medicineRegimenOncologyVinorelbineCancerAdenocarcinomaMetastatic breast cancerGastroenterologyChemotherapyBreast cancerCisplatinGastric Cancer Management and OutcomesHER2/EGFR in Cancer ResearchAdvanced Breast Cancer Therapies